Thesis Capital Inc.

NurExone Biologic (TSXV: NRX)(OTCQB:NRXBF)(FSE: J90) ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market The company is pleased to announce a pre-clinical study to explore the potential of NurExone’s exosome-based therapies in regenerating damaged optic nerves. The study, initiated by renowned ophthalmologist and serial entrepreneur Prof. Michael Belkin from Tel Aviv University's Goldschleger Eye Research Institute, and led by the principal investigators Prof. Ygal Rotenstreich and Dr. Ifat Sher from the Sheba Medical Center Eye Institute, is the latest step in expanding potential clinical indications for Nurexone Biologic's exosome-loaded drugs. Press Release Link: https://lnkd.in/gcz7FhjF

Happy Canada Day!

Scientists Giving New Hope to People With Spinal Cord Injuries "There is a possibility to give hope to many people who would otherwise be disabled," say directors at NurExone Biologic, a company established to develop and commercialize this innovative technology. Full news: https://lnkd.in/dcvP-a23

On Path to First-in-Human Study, NurExone Biologic (TSXV: NRX)(OTCQB:NRXBF)(FSE: J90) Engages Prominent Expert in Biological Drug Development NurExone welcomes Dr. Yona Geffen, as a consultant, to support the Company’s preclinical and clinical activities. Dr. Geffen, who currently serves as Vice President of Research and Development at Gamida Cell Ltd., brings over two decades of extensive experience in leading clinical and drug development in the biotechnology and pharmaceutical industries. Under her leadership, Gamida Cell obtained United States Food and Drug Administration approval for Omisirge®, a groundbreaking stem cell therapy. Press Release Link: https://lnkd.in/gcA3gpm2

Global Education Communities Corp. (TSX: GEC | OTCQX: GECSF) Provides Updates on its Corporate Activities 🔹After 2.5 years of litigation for GECC's investments in the Atmosphere project, the trial was completed on May 31, 2024, and the court's decision is expected in the coming weeks. 🔹GEC® Oakridge construction is expected to start in Q4 2024. 🔹GEC® Oakridge has submitted a CMHC loan application for $120M in May, and we expect positive results in June or July, which ties in nicely with the recent decline in the Bank of Canada interest rate and Canada's government bond rates. 🔹Application has been made to double the rezoning height for GEC® Langara via the TOA rezoning legislation, allowing for much higher density and minimal parking requirements. 🔹In September 2023, the federal government announced the GST exemption for all rental project developments, reducing development costs significantly. 🔹Revision of the development plan for GEC® EMC is nearly complete for submission to the City of Surrey. 🔹GEC® Kingsway will come online in July and will be ready for occupancy by September. 🔹GEC® Viva is undergoing renovation which is expected to be completed by September. 🔹Most GEC® operating properties are at near-full capacity. Press Release Link: https://lnkd.in/gZte5YRx #realestate #realestatemarket #educationmarket #housingmarket #studenthousing #Vancouver #BritishColumbia #Canada #rentalcrisis #realestatestocks #educationstocks #microcap #TSX #OTCQX #stocks #stockmarket #stocknews #stockstowatch #stockstobuy #invest #investors #investing #whatsyourthesis

NurExone Biologic (TSXV: NRX)(OTCQB:NRXBF)(FSE: J90) Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application The patent, titled “Vesicles Comprising a PTEN Inhibitor and Uses of Same”, was originally submitted by the Technion Research and Development Foundation Ltd. (“Technion”) and Ramot at Tel Aviv University Ltd. It is the first patent licensed by NurExone from Technion and describes a fundamental element of the Company’s ExoPTEN nanodrug under development for acute spinal cord injury. Press Release Link: https://lnkd.in/gSWKVAJa #lifescience #healthcare #biotech #medtech #spinalcordinjury #spinalinjury #braininjury #traumaticbraininjury #technology #medicine #treatment #therapeutics #drugdiscovery #stock #investing #investor #stockmarket #stockstowatch #whatsyourthesis

Litchfield Hills Research provides an update on NurExone Biologic (TSXV: NRX)(OTCQB:NRXBF)(FSE: J90) and reiterates its buy rating and price target of $4.00/share. Key Highlights: 🔹NurExone exceeded Q1 2024 expectations by reporting an EPS loss of $0.016 versus loss estimate of $0.022. 🔹Shares appear to be priced below absolute and comparative metrics based on discounted future earnings. 🔹Expanded preclinical testing: Contract Research Organization services agreement with Vivox Ltd. for animal experiments. 🔹Lab expansion: NurExone executed a lease for lab space with the Technion. 🔹Key hire in licensing efforts: NurExone hired Dr. Ram Petter, Ph.D., MBA, as a consultant. 🔹Broadening market reach in the United States: NurExone received listing approval on the OTCQB and DTC eligibility under the symbol (OTCQB: NRXBF). 🔹Revision to estimate: With the higher share count, NurExone's EPS losses for 2024 and 2025 decline to $0.08 from a loss of $0.09. Click the attachment below to read the full report. #lifescience #healthcare #biotech #medtech #spinalcordinjury #spinalinjury #braininjury #traumaticbraininjury #technology #medicine #treatment #therapeutics #drugdiscovery #stock #investing #investor #stockmarket #stockstowatch #whatsyourthesis

NurExone Biologic (TSXV: NRX)(OTCQB:NRXBF)(FSE: J90) Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials 🔹Setup of in-house laboratories and offices to bolster its research and development capabilities 🔹Entered into a Contract Research Organization services agreement with Vivox Ltd. for animal experiments as part of the preclinical testing phase for the submission of an IND application to the US FDA 🔹Secured approval for listing on the OTCQB Press Release Link: https://lnkd.in/g4DB44dM #lifescience #healthcare #biotech #medtech #spinalcordinjury #spinalinjury #braininjury #traumaticbraininjury #technology #medicine #treatment #therapeutics #drugdiscovery #stock #investing #investor #stockmarket #stockstowatch #whatsyourthesis

Heritage Mining Ltd. (CSE: HML | FRA: Y66) Commences 2024 Exploration Season at Expanded Drayton-Black Lake Select Transaction Highlights & Comments DBL Target - Zone 3: - 3D model for evaluation and confirmation drilling of the historical 1980 Non 43-101 Compliant Mineral Resource of 70,000 tonnes at 8.16g/t Au high-grade ore shoot, near surface - Property expansion along Zone 3 gold-bearing Contact Zone 3 through to Zone 10 DBL Exploration Update: - Soil Sampling (Spatiotemporal-Gas-Hydrocarbon (SGH)) & mapping commencement (Figures 7, 8), results pending - Diamond drilling to commence late Q2 2024 Structural Interpretation and Geological Modeling: - Property wide structural interpretation (Figure 9) and 3D geological model (32km EW by 25km NW by 3km vertical extent) Press Release Link: https://lnkd.in/eNuez5df #Mining #miningindustry #grants #miningnews #DistrictScaleDiscovery #Exploration #gold #VMS #OJEP #resources #juniorresources #juniormining #fourthtranche #smallcapmining #smallcapresources #Canada #TSXV #SmallCapStocks #smallcap #microcap #MicroCapStocks

NurExone Biologic (TSXV: NRX)(OTCQB:NRXBF)(FSE: J90) Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations With a distinguished background in the pharmaceutical industry, including significant tenure and pivotal roles at Teva Pharmaceuticals, Dr. Petter’s addition signals NurExone’s readiness for industry partnerships and licensing agreements. Press Release Link: https://lnkd.in/eP23NVXn #lifescience #healthcare #biotech #medtech #spinalcordinjury #spinalinjury #braininjury #traumaticbraininjury #technology #medicine #treatment #therapeutics #drugdiscovery #stock #investing #investor #stockmarket #stockstowatch #whatsyourthesis